Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to establish the safety of administration of intranasal Foralumab in
non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple
ascending dose format in escalating doses for 14 consecutive days.